Table 4: INR-related claims among all OAC users during the 6-month follow-up.
| – |
Overall |
Apixaban Cohort |
Dabigatran Cohort |
Rivaroxaban Cohort |
Warfarin Cohort |
| N/Mean |
STD/% |
N/Mean |
STD/% |
N/Mean |
STD/% |
N/Mean |
STD/% |
N/Mean |
STD/% |
| Patients |
468 |
|
147 |
|
98 |
|
156 |
|
67 |
|
| Number of INR-related claims* |
|
|
|
|
|
|
|
|
|
|
| Overall
|
|
|
|
|
|
|
|
|
|
|
| N with 180 days of follow-up |
306 |
65% |
85 |
58% |
65 |
66% |
111 |
71% |
45 |
67% |
| Mean |
1.5 |
5.6 |
0.9 |
2.6 |
0.7 |
2.8 |
0.7 |
2.9 |
6.1 |
12.3 |
| For patients with at least 1 INR-related claim |
|
|
|
|
|
|
|
|
|
|
| N |
73 |
16% |
18 |
12% |
7 |
7% |
21 |
13% |
27 |
40% |
| Mean |
6.3 |
10.2 |
4.1 |
4.3 |
6.0 |
6.8 |
3.5 |
5.8 |
10.1 |
14.6 |
| Median |
2.0 |
|
2.0 |
|
3.0 |
|
2.0 |
|
3.0 |
|
| Min |
1.0 |
|
1.0 |
|
1.0 |
|
1.0 |
|
1.0 |
|
| Max |
68.0 |
|
17.0 |
|
20.0 |
|
28.0 |
|
68.0 |
|
| 0 |
233 |
76.1% |
67 |
78.8% |
58 |
89.2% |
90 |
81.1% |
18 |
40.0% |
| 1 |
23 |
7.5% |
8 |
9.4% |
2 |
3.1% |
8 |
7.2% |
5 |
11.1% |
| 2 |
14 |
4.6% |
2 |
2.4% |
1 |
1.5% |
7 |
6.3% |
4 |
8.9% |
| 3 |
8 |
2.6% |
1 |
1.2% |
1 |
1.5% |
1 |
0.9% |
5 |
11.1% |
| 4+ |
28 |
9.2% |
7 |
8.2% |
3 |
4.6% |
5 |
4.5% |
13 |
28.9% |
| Time (in days) from index date to first INR-related claim |
|
|
|
|
|
|
|
|
|
|
| N |
73 |
|
18 |
|
7 |
|
21 |
|
27 |
|
| Mean |
34.9 |
47.9 |
37.3 |
58.9 |
70.7 |
70.5 |
24.4 |
|
32.2 |
38.8 |
| Median |
7.0 |
|
1.0 |
|
67.0 |
|
1.0 |
|
10.0 |
|
| Min |
1.0 |
|
1.0 |
|
1.0 |
|
1.0 |
|
1.0 |
|
| Max |
178.0 |
|
178.0 |
|
162.0 |
|
112.0 |
|
117.0 |
|
STD: standardized difference;
*INR-related claim was defined based on CPT code 85610 - Prothrombin Time (PT)